Scleroderma Therapeutics Market | Acumen Research and Consulting
Scleroderma Therapeutics Market Size - Global Industry, Share, Analysis, Trends and Forecast 2022 - 2030
Published :
Report ID:
Pages :
Format : 
CHAPTER 1. Industry Overview of Scleroderma Therapeutics Market
1.1. Definition and Scope
1.1.1. Definition of Scleroderma Therapeutics
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Scleroderma Therapeutics Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Scleroderma Therapeutics Market By Drug Class
1.2.3. Scleroderma Therapeutics Market By Indication
1.2.4. Scleroderma Therapeutics Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Scleroderma Therapeutics Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Scleroderma Therapeutics Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2021
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Scleroderma Therapeutics Market By Drug Class
4.1. Introduction
4.2. Scleroderma Therapeutics Revenue By Drug Class
4.2.1. Scleroderma Therapeutics Revenue (USD Million) and Forecast, By Drug Class, 2018-2030
4.2.2. Immunosuppressors
4.2.2.1. Immunosuppressors Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.3. Analgesic
4.2.3.1. Analgesic Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.4. Phosphodiesterase 5 Inhibitors - PHA
4.2.4.1. Phosphodiesterase 5 Inhibitors - PHA Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.5. Endothelin Receptor Antagonists
4.2.5.1. Endothelin Receptor Antagonists Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.6. Calcium Channel Blockers
4.2.6.1. Calcium Channel Blockers Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.7. Prostacyclin Analogues
4.2.7.1. Prostacyclin Analogues Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.8. Others
4.2.8.1. Others Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 5. Scleroderma Therapeutics Market By Indication
5.1. Introduction
5.2. Scleroderma Therapeutics Revenue By Indication
5.2.1. Scleroderma Therapeutics Revenue (USD Million) and Forecast, By Indication, 2018-2030
5.2.2. Systemic
5.2.2.1. Systemic Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.3. Localized
5.2.3.1. Localized Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 6. North America Scleroderma Therapeutics Market By Country
6.1. North America Scleroderma Therapeutics Market Overview
6.2. U.S.
6.2.1. U.S. Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
6.2.2. U.S. Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
6.3. Canada
6.3.1. Canada Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
6.3.2. Canada Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
6.4. North America PEST Analysis
CHAPTER 7. Europe Scleroderma Therapeutics Market By Country
7.1. Europe Scleroderma Therapeutics Market Overview
7.2. U.K.
7.2.1. U.K. Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
7.2.2. U.K. Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
7.3. Germany
7.3.1. Germany Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
7.3.2. Germany Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
France
7.3.3. France Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
7.3.4. France Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
7.4. Spain
7.4.1. Spain Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
7.4.2. Spain Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
7.5. Rest of Europe
7.5.1. Rest of Europe Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
7.5.2. Rest of Europe Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
7.6. Europe PEST Analysis
CHAPTER 8. Asia Pacific Scleroderma Therapeutics Market By Country
8.1. Asia Pacific Scleroderma Therapeutics Market Overview
8.2. China
8.2.1. China Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.2.2. China Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
8.3. Japan
8.3.1. Japan Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.3.2. Japan Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
8.4. India
8.4.1. India Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.4.2. India Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
8.5. Australia
8.5.1. Australia Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.5.2. Australia Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
8.6. South Korea
8.6.1. South Korea Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.6.2. South Korea Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
8.7. Rest of Asia-Pacific
8.7.1. Rest of Asia-Pacific Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.7.2. Rest of Asia-Pacific Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
8.8. Asia Pacific PEST Analysis
CHAPTER 9. Latin America Scleroderma Therapeutics Market By Country
9.1. Latin America Scleroderma Therapeutics Market Overview
9.2. Brazil
9.2.1. Brazil Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
9.2.2. Brazil Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
9.3. Mexico
9.3.1. Mexico Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
9.3.2. Mexico Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
9.4. Rest of Latin America
9.4.1. Rest of Latin America Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
9.4.2. Rest of Latin America Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
9.5. Latin America PEST Analysis
CHAPTER 10. Middle East & Africa Scleroderma Therapeutics Market By Country
10.1. Middle East & Africa Scleroderma Therapeutics Market Overview
10.2. GCC
10.2.1. GCC Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
10.2.2. GCC Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
10.3. South Africa
10.3.1. South Africa Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
10.3.2. South Africa Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
10.4. Rest of Middle East & Africa
10.4.1. Rest of Middle East & Africa Scleroderma Therapeutics Revenue (USD Million) and Forecast By Drug Class, 2018-2030
10.4.2. Rest of Middle East & Africa Scleroderma Therapeutics Revenue (USD Million) and Forecast By Indication, 2018-2030
10.5. Middle East & Africa PEST Analysis
CHAPTER 11. Player Analysis Of Scleroderma Therapeutics Market
11.1. Scleroderma Therapeutics Market Company Share Analysis
11.2. Competition Matrix
11.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
11.2.2. New Product Launches and Product Enhancements
11.2.3. Mergers And Acquisition In Global Scleroderma Therapeutics Market
11.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 12. Company Profile
12.1. Active Biotech AB
12.1.1. Company Snapshot
12.1.2. Business Overview
12.1.3. Financial Overview
12.1.3.1. Revenue (USD Million), 2021
12.1.3.2. Active Biotech AB 2021 Scleroderma Therapeutics Business Regional Distribution
12.1.4. Product/Service and Specification
12.1.5. Recent Developments & Business Strategy
12.2. Daval International Ltd.
12.3. BioLineRx, Ltd.
12.4. Corbus pharmaceuticals, Inc.
12.5. F. Hoffmann-La Roche Ltd.
12.6. GlaxoSmithKline plc
12.7. Angion Biomedica Corp.
12.8. Fibrocell Science, Inc.
12.9. Bayer AG
12.10. Bristol-Myers Squibb Company
12.11. Allergan, Inc.
12.12. Dynavax Technologies Corporation
Frequently Asked Questions
What is the size of global scleroderma therapeutics market in 2021?
The estimated value of global scleroderma therapeutics market in 2021 was accounted to be USD 2,912 Million.
What is the CAGR of global scleroderma therapeutics market during forecast period of 2022 to 2030?
The projected CAGR scleroderma therapeutics market during the analysis period of 2022 to 2030 is 6.4%.
Which are the key players operating in the market?
The prominent players of the global scleroderma therapeutics market are Active Biotech AB, Daval International Ltd., BioLineRx, Ltd., Corbus pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Angion Biomedica Corp., Fibrocell Science, Inc., Bayer AG, Bristol-Myers Squibb Company, Allergan, Inc., and Dynavax Technologies Corporation.
Which region held the dominating position in the global scleroderma therapeutics market?
North America held the dominating scleroderma therapeutics during the analysis period of 2022 to 2030.
Which region registered the fastest growing CAGR for the forecast period of 2022 to 2030?
Asia-Pacific region exhibited fastest growing CAGR for scleroderma therapeutics during the analysis period of 2022 to 2030.
What are the current trends and dynamics in the global scleroderma therapeutics market?
Growing incidence of scleroderma, and increasing pharmaceutical companies' focus on developing novel drugs drives the growth of global scleroderma therapeutics market.
By indication segment, which sub-segment held the maximum share?
Based on indication, systemic segment is expected to hold the maximum share scleroderma therapeutics market.
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
